Stockreport

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy [Yahoo! Finance]

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF E valuation of D osing with A ficamten to R educe Obstruction in a Pediatric Population in HCM ), a clinical trial of aficamten in a pediatric population with symptomati [Read more]